233 related articles for article (PubMed ID: 34880055)
1. Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.
Krzyzanowska MK; Julian JA; Gu CS; Powis M; Li Q; Enright K; Howell D; Earle CC; Gandhi S; Rask S; Brezden-Masley C; Dent S; Hajra L; Freeman O; Spadafora S; Hamm C; Califaretti N; Trudeau M; Levine MN; Amir E; Bordeleau L; Chiarotto JA; Elser C; Husain J; Laferriere N; Rahim Y; Robinson AG; Vandenberg T; Grunfeld E
BMJ; 2021 Dec; 375():e066588. PubMed ID: 34880055
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
Krzyzanowska MK; Julian JA; Powis M; Howell D; Earle CC; Enright KA; Mittmann N; Trudeau ME; Grunfeld E
BMC Cancer; 2019 Sep; 19(1):884. PubMed ID: 31488084
[TBL] [Abstract][Full Text] [Related]
3. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART).
Maguire R; McCann L; Kotronoulas G; Kearney N; Ream E; Armes J; Patiraki E; Furlong E; Fox P; Gaiger A; McCrone P; Berg G; Miaskowski C; Cardone A; Orr D; Flowerday A; Katsaragakis S; Darley A; Lubowitzki S; Harris J; Skene S; Miller M; Moore M; Lewis L; DeSouza N; Donnan PT
BMJ; 2021 Jul; 374():n1647. PubMed ID: 34289996
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer.
Krzyzanowska MK; MacKay C; Han H; Eberg M; Gandhi S; Laferriere NB; Powis M; Howell D; Atzema CL; Chan KKW; Kukreti V; Mitchell S; Nayer M; Pasetka M; Knittel-Keren D; Redwood E
Pilot Feasibility Stud; 2019; 5():39. PubMed ID: 30891308
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
Nyrop KA; Deal AM; Shachar SS; Basch E; Reeve BB; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Reeder-Hayes KE; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Oncologist; 2019 Jun; 24(6):762-771. PubMed ID: 30552158
[TBL] [Abstract][Full Text] [Related]
7. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
[TBL] [Abstract][Full Text] [Related]
8. The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial.
Breen S; Ritchie D; Schofield P; Hsueh YS; Gough K; Santamaria N; Kamateros R; Maguire R; Kearney N; Aranda S
Trials; 2015 Oct; 16():472. PubMed ID: 26481873
[TBL] [Abstract][Full Text] [Related]
9. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial.
Steventon A; Bardsley M; Billings J; Dixon J; Doll H; Hirani S; Cartwright M; Rixon L; Knapp M; Henderson C; Rogers A; Fitzpatrick R; Hendy J; Newman S;
BMJ; 2012 Jun; 344():e3874. PubMed ID: 22723612
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
11. Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial.
Traeger L; McDonnell TM; McCarty CE; Greer JA; El-Jawahri A; Temel JS
Cancer; 2015 Nov; 121(21):3905-13. PubMed ID: 26194461
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
13. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
14. Handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy in a cluster randomized trial with electronic patient-reported outcomes as intervention.
Baeksted CW; Nissen A; Knoop A; Christiansen M; Pappot H
Breast J; 2019 Nov; 25(6):1295-1296. PubMed ID: 31353754
[No Abstract] [Full Text] [Related]
15. Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer.
Pittman NM; Hopman WM; Mates M
J Oncol Pract; 2015 Mar; 11(2):120-5. PubMed ID: 25585617
[TBL] [Abstract][Full Text] [Related]
16. Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy.
Tang M; Horsley P; Lewis CR
Intern Med J; 2018 May; 48(5):583-587. PubMed ID: 29722200
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
18. Patient Use and Clinical Practice Patterns of Remote Cardiology Clinic Visits in the Era of COVID-19.
Yuan N; Pevnick JM; Botting PG; Elad Y; Miller SJ; Cheng S; Ebinger JE
JAMA Netw Open; 2021 Apr; 4(4):e214157. PubMed ID: 33818619
[TBL] [Abstract][Full Text] [Related]
19. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
20. Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomised controlled trial.
McGillion MH; Parlow J; Borges FK; Marcucci M; Jacka M; Adili A; Lalu MM; Ouellette C; Bird M; Ofori S; Roshanov PS; Patel A; Yang H; O'Leary S; Tandon V; Hamilton GM; Mrkobrada M; Conen D; Harvey V; Lounsbury J; Mian R; Bangdiwala SI; Arellano R; Scott T; Guyatt GH; Gao P; Graham M; Nenshi R; Forster AJ; Nagappa M; Levesque K; Marosi K; Chaudhry S; Haider S; Deuchar L; LeBlanc B; McCartney CJL; Schemitsch EH; Vincent J; Pettit SM; DuMerton D; Paulin AD; Simunovic M; Williams DC; Halman S; Harlock J; Meyer RM; Taylor DA; Shanthanna H; Schlachta CM; Parry N; Pichora DR; Yousuf H; Peter E; Lamy A; Petch J; Moloo H; Sehmbi H; Waggott M; Shelley J; Belley-Cote EP; Devereaux PJ;
BMJ; 2021 Sep; 374():n2209. PubMed ID: 34593374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
